Yervoy (ipilimumab)

P2, N=66, Active, not recruiting, Ontario Clinical Oncology Group (OCOG) | Trial completion date: Apr 2026 --> Jul 2026

As surgical resection was not feasible, first-line treatment with ipilimumab plus nivolumab combined with chemotherapy was initiated, resulting in a partial response...Thirteen months later, the patient developed radiographic worsening of ILD, for which oral prednisolone was initiated...The patient received two cycles of nab-paclitaxel plus carboplatin without response and subsequently died. These findings emphasize that clinicians should recognize that IMA may undergo sarcomatous transformation.

P2, N=107, Active, not recruiting, Tianjin Medical University Cancer Institute and Hospital

P1/2, N=41, Active, not recruiting, Ravi Amaravadi, MD | Recruiting --> Active, not recruiting | N=94 --> 41 | Trial completion date: Jan 2027 --> May 2027 | Trial primary completion date: Jan 2027 --> Jul 2026

P2, N=39, Recruiting, University of Chicago | Not yet recruiting --> Recruiting

P=N/A, N=623, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed

The ipilimumab-pembrolizumab combination demonstrated the highest reporting odds ratio (97.2, 95% CI: 58.1-162.4). Integration of pharmacovigilance and transcriptomic data implicates coordinated effects of melanocyte-lineage antigens, innate immune and mitochondrial function pathways in vitiligo pathogenesis. This study aimed to systematically characterize the risk profile, onset timing, and potential biological mechanisms of ICI-induced vitiligo across different treatment strategies and cancer types.

P2, N=50, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended

In this large real-world cohort, first-line NIVO + IPI therapy demonstrated meaningful clinical activity and an acceptable safety profile in advanced ESCC. Treatment outcomes varied according to metastatic patterns, suggesting an influence of organ-specific immune microenvironments, and CAR emerged as a simple and robust prognostic biomarker. These findings support the real-world applicability of dual immune checkpoint blockade and highlight the importance of host immune context in patient selection.

P2, N=23, Not yet recruiting, Sun Yat-sen University

Dual CTLA-4/PD-1 blockade improved PFS and OS versus anti-PD-1 alone, driven by higher early response rates. Female sex, absence of liver metastases, and left-sided tumor location may predict greater benefit from combination.

IgG from melanoma patients treated with pembrolizumab, nivolumab, or ipilimumab, with or without severe colitis, was transferred into wild-type or humanized FcγR (hFcγR) mice receiving comparable ICI therapy. Single-cell RNA sequencing identified an IgG-regulated inflammatory network involving IFNg-producing ILC1, Th1 and cytotoxic T cells, IL-1betta-M1 macrophages, plasma B cells/plasmablasts, and IL-22-producing ILC3-LTi cells. Patient serum autoantibody profiling further identified CCR5 and CXCR4 receptors as candidate immune-related targets associated with ICC susceptibility.